Cargando…
The course of subjective and objective chemosensory dysfunction in hospitalized patients with COVID-19: a 6-month follow-up
PURPOSE: It has been established that the infection with SARS-CoV-2 may cause an impairment of chemosensory function. However, there is little data on the long-term effects of SARS-CoV-2 infection on chemosensory function. METHODS: Twenty three SARS-CoV-2-positive patients diagnosed in spring 2020 w...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035606/ https://www.ncbi.nlm.nih.gov/pubmed/33837835 http://dx.doi.org/10.1007/s00405-021-06796-4 |
_version_ | 1783676735115493376 |
---|---|
author | Bertlich, Mattis Stihl, Clemens Lüsebrink, Enzo Hellmuth, Johannes C. Scherer, Clemens Freytag, Saskia Spiegel, Jennifer Lee Stoycheva, Ivelina Canis, Martin Weiss, Bernhard G. Ihler, Friedrich Haubner, Frank |
author_facet | Bertlich, Mattis Stihl, Clemens Lüsebrink, Enzo Hellmuth, Johannes C. Scherer, Clemens Freytag, Saskia Spiegel, Jennifer Lee Stoycheva, Ivelina Canis, Martin Weiss, Bernhard G. Ihler, Friedrich Haubner, Frank |
author_sort | Bertlich, Mattis |
collection | PubMed |
description | PURPOSE: It has been established that the infection with SARS-CoV-2 may cause an impairment of chemosensory function. However, there is little data on the long-term effects of SARS-CoV-2 infection on chemosensory function. METHODS: Twenty three SARS-CoV-2-positive patients diagnosed in spring 2020 with subjective hyposmia (out of 57 positive patients, 40.3%) were compared to SARS-CoV-2-positive patients without hyposmia (n = 19) and SARS-CoV-2-negative patients (n = 14). Chemosensory function was assessed by the Brief Smell Identification Test (BSIT), Taste Strips (TS), Visual Analogue Scales (VAS), and the SNOT-22. The initial cohort with hyposmia were also examined at 8 weeks and 6 months after initial examination. RESULTS: There were no differences between the SARS-CoV-2-positive cohort without hyposmia and negative controls in terms of BSIT (8.5 ± 2.6 vs. 10.2 ± 1.8), TS (3.4 ± 0.6 vs. 3.9 ± 0.3) or VAS (2.1 ± 1.3 vs. 1.1 ± 0.5); yet the SNOT-22 was significantly elevated (27.7 ± 11.2 vs. 16.4 ± 10.8). The SARS-CoV-2-positive group with hyposmia performed significantly poorer in BSIT (4.0 ± 1.7 vs. 8.5 ± 2.6/10.2 ± 1.8), TS (2.6 ± 1.3 vs. 3.4 ± 0.6/3.9 ± 0.3), and VAS (7.9 ± 2.2 vs. 2.1 ± 1.3/1.1 ± 0.5) compared to both control groups. At week 8 and month 6 control, six and five patients, respectively, still suffered from subjectively and objectively impaired chemosensory function. The other patients had recovered in both respects. CONCLUSION: SARS-CoV-2 patients with subjectively impaired chemosensory function regularly perform poorly in objective measurements. About 70% of patients suffering from olfactory dysfunction in SARS-CoV-2 quickly recover—the rest still suffers from considerable impairment 6 months after infection. |
format | Online Article Text |
id | pubmed-8035606 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-80356062021-04-12 The course of subjective and objective chemosensory dysfunction in hospitalized patients with COVID-19: a 6-month follow-up Bertlich, Mattis Stihl, Clemens Lüsebrink, Enzo Hellmuth, Johannes C. Scherer, Clemens Freytag, Saskia Spiegel, Jennifer Lee Stoycheva, Ivelina Canis, Martin Weiss, Bernhard G. Ihler, Friedrich Haubner, Frank Eur Arch Otorhinolaryngol Rhinology PURPOSE: It has been established that the infection with SARS-CoV-2 may cause an impairment of chemosensory function. However, there is little data on the long-term effects of SARS-CoV-2 infection on chemosensory function. METHODS: Twenty three SARS-CoV-2-positive patients diagnosed in spring 2020 with subjective hyposmia (out of 57 positive patients, 40.3%) were compared to SARS-CoV-2-positive patients without hyposmia (n = 19) and SARS-CoV-2-negative patients (n = 14). Chemosensory function was assessed by the Brief Smell Identification Test (BSIT), Taste Strips (TS), Visual Analogue Scales (VAS), and the SNOT-22. The initial cohort with hyposmia were also examined at 8 weeks and 6 months after initial examination. RESULTS: There were no differences between the SARS-CoV-2-positive cohort without hyposmia and negative controls in terms of BSIT (8.5 ± 2.6 vs. 10.2 ± 1.8), TS (3.4 ± 0.6 vs. 3.9 ± 0.3) or VAS (2.1 ± 1.3 vs. 1.1 ± 0.5); yet the SNOT-22 was significantly elevated (27.7 ± 11.2 vs. 16.4 ± 10.8). The SARS-CoV-2-positive group with hyposmia performed significantly poorer in BSIT (4.0 ± 1.7 vs. 8.5 ± 2.6/10.2 ± 1.8), TS (2.6 ± 1.3 vs. 3.4 ± 0.6/3.9 ± 0.3), and VAS (7.9 ± 2.2 vs. 2.1 ± 1.3/1.1 ± 0.5) compared to both control groups. At week 8 and month 6 control, six and five patients, respectively, still suffered from subjectively and objectively impaired chemosensory function. The other patients had recovered in both respects. CONCLUSION: SARS-CoV-2 patients with subjectively impaired chemosensory function regularly perform poorly in objective measurements. About 70% of patients suffering from olfactory dysfunction in SARS-CoV-2 quickly recover—the rest still suffers from considerable impairment 6 months after infection. Springer Berlin Heidelberg 2021-04-10 2021 /pmc/articles/PMC8035606/ /pubmed/33837835 http://dx.doi.org/10.1007/s00405-021-06796-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Rhinology Bertlich, Mattis Stihl, Clemens Lüsebrink, Enzo Hellmuth, Johannes C. Scherer, Clemens Freytag, Saskia Spiegel, Jennifer Lee Stoycheva, Ivelina Canis, Martin Weiss, Bernhard G. Ihler, Friedrich Haubner, Frank The course of subjective and objective chemosensory dysfunction in hospitalized patients with COVID-19: a 6-month follow-up |
title | The course of subjective and objective chemosensory dysfunction in hospitalized patients with COVID-19: a 6-month follow-up |
title_full | The course of subjective and objective chemosensory dysfunction in hospitalized patients with COVID-19: a 6-month follow-up |
title_fullStr | The course of subjective and objective chemosensory dysfunction in hospitalized patients with COVID-19: a 6-month follow-up |
title_full_unstemmed | The course of subjective and objective chemosensory dysfunction in hospitalized patients with COVID-19: a 6-month follow-up |
title_short | The course of subjective and objective chemosensory dysfunction in hospitalized patients with COVID-19: a 6-month follow-up |
title_sort | course of subjective and objective chemosensory dysfunction in hospitalized patients with covid-19: a 6-month follow-up |
topic | Rhinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035606/ https://www.ncbi.nlm.nih.gov/pubmed/33837835 http://dx.doi.org/10.1007/s00405-021-06796-4 |
work_keys_str_mv | AT bertlichmattis thecourseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup AT stihlclemens thecourseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup AT lusebrinkenzo thecourseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup AT hellmuthjohannesc thecourseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup AT schererclemens thecourseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup AT freytagsaskia thecourseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup AT spiegeljenniferlee thecourseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup AT stoychevaivelina thecourseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup AT canismartin thecourseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup AT weissbernhardg thecourseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup AT ihlerfriedrich thecourseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup AT haubnerfrank thecourseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup AT bertlichmattis courseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup AT stihlclemens courseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup AT lusebrinkenzo courseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup AT hellmuthjohannesc courseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup AT schererclemens courseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup AT freytagsaskia courseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup AT spiegeljenniferlee courseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup AT stoychevaivelina courseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup AT canismartin courseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup AT weissbernhardg courseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup AT ihlerfriedrich courseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup AT haubnerfrank courseofsubjectiveandobjectivechemosensorydysfunctioninhospitalizedpatientswithcovid19a6monthfollowup |